Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments.

ABSTRACT:

Background

Vaccination against SARS CoV-2 results in excellent personal protection against a severe course of COVID19. In People with Multiple Sclerosis (PwMS) vaccination efficacy may be reduced by immunomodulatory medications.

Objective

To assess the vaccination induced cellular and humoral immune response in PwMS receiving disease modifying therapies.

Methods

In a monocentric observational study on PwMS and patients with Neuromyelitis optica we quantified the cellular and humoral immune responses to SARS CoV-2.

Results

PwMS receiving glatiramer acetate, Interferon-ß, Dimethylfumarate, Cladribine or Natalizumab had intact humoral and cellular immune responses following vaccination against SARS CoV-2. B-cell depleting therapies reduced B-cell responses but did

SUBMITTER: Bock H 

PROVIDER: S-EPMC8783535 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature